302 related articles for article (PubMed ID: 12109800)
1. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
2. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Feig B; Mansfield PF
Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):52-4. PubMed ID: 11301842
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Ajani JA; Fairweather J; Pisters PW; Charnsangavej C
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):19-21. PubMed ID: 11200143
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Cancer Chemother Pharmacol; 2011 Jan; 67(1):75-82. PubMed ID: 20198372
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Blanke CD; Haller DG; Benson AB; Rothenberg ML; Berlin J; Mori M; Hsieh YC; Miller LL
Ann Oncol; 2001 Nov; 12(11):1575-80. PubMed ID: 11822757
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Dank M; Zaluski J; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Cisar L; Wang K; Bugat R
Ann Oncol; 2008 Aug; 19(8):1450-1457. PubMed ID: 18558665
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Koutras AK; Gerolymos MK; Kontogeorgou E; Iconomou G; Vourli G; Tsiata E; Makatsoris T; Chrysanthopoulos C; Kalofonos HP
J Chemother; 2007 Dec; 19(6):724-30. PubMed ID: 18230557
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Pozzo C; Barone C; Szanto J; Padi E; Peschel C; Bükki J; Gorbunova V; Valvere V; Zaluski J; Biakhov M; Zuber E; Jacques C; Bugat R
Ann Oncol; 2004 Dec; 15(12):1773-81. PubMed ID: 15550582
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
Janjigian YY; Ku GY; Campbell JC; Shah MA; Capanu M; Kelsen DP; Ilson DH
Am J Clin Oncol; 2014 Apr; 37(2):126-30. PubMed ID: 23211227
[TBL] [Abstract][Full Text] [Related]
17. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
Lim WT; Lim ST; Wong NS; Koo WH
J Chemother; 2003 Aug; 15(4):400-5. PubMed ID: 12962370
[TBL] [Abstract][Full Text] [Related]
18. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
[TBL] [Abstract][Full Text] [Related]
19. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
